Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

Salix Pharmaceuticals stock rose 5 percent last week despite news that the company received a warning letter from the Food and Drug Administration (FDA) urging the company to clarify information about its new orally dissolving heartburn treatment, Metozolv ODT, according to Local Tech Wire. The FDA said that some of the drug’s marketing materials are “false or misleading because they omit and minimize risk information, broaden the indication of Metozolv ODT, and contain unsubstantiated comparative and other claims.”

Read the rest of this entry »

In the February 1996 issue of the drug newsletter Worst Pills, Best Pills News, a story was published by the Health Research Group of Public Citizen warning that a drug commonly prescribed for heartburn and slow emptying of the stomach contents, a condition known as gastroparesis, could cause a serious movement disorder known as Tardive Dyskinesia. The condition could cause permanent disability in users, according to the report.

However, it took more than a decade for the Food and Drug Administration (FDA) to place a black box warning on the medication, Reglan. A black box warning is the strongest warning issued by the FDA and is placed on drugs that have potentially harmful or deadly side effects. Meanwhile, the drug was dispensed 6.5 million times in 2008 to an estimated 2 million Americans.

Read the rest of this entry »

Heartburn and gastroesophageal reflux (GER) occur when the lower esophageal sphincter opens spontaneously or does not close properly, allowing stomach contents to rise up into the esophagus. GER is also called acid reflux or acid regurgitation, and when it occurs, food or fluid can be tasted in the back of the mouth and may cause a burning sensation in the chest or throat.

Read the rest of this entry »